Navigation Links
FDA Asks Docs to Suspend Using Glaxo Rotavirus Vaccine
Date:3/22/2010

Rotarix is contaminated with pig virus but poses no known health risk, officials say,,

MONDAY, March 22 (HealthDay News) -- U.S. health officials recommended Monday that doctors temporarily stop using the Rotarix vaccine -- one of two brands available to prevent the diarrhea bug rotavirus -- for children until the source and any potential harm from a contamination of the vaccine has been identified.

Doses of the oral vaccine appear to be contaminated with a benign pig virus, according to officials at the U.S. Food and Drug Administration.

The recommendation comes after independent researchers found porcine circovirus 1 (PCV1) in Rotarix. This virus is not known to cause illness in humans, FDA Commissioner Dr. Margaret Hamburg said during an afternoon teleconference.

"There is no evidence at this time that this material from PCV1 in Rotarix poses any safety risk," Hamburg said. "PCV1 is not known to cause any disease in humans or animals."

Still, vaccines are supposed to be sterile and although Rotarix has a good safety record, finding PCV1 in the vaccine was unexpected, Hamburg said. Rotarix, made by drug giant GlaxoSmithKline, was licensed in 2008.

"While the agency is learning more about the situation, FDA is recommending that clinicians temporarily suspend the use of Rotarix vaccine," Hamburg said.

Rotavirus is a common cause of severe diarrhea among children, hospitalizing approximately 55,000 children each year in the United States. The virus is responsible for more than 600,000 children's deaths each year worldwide. The disease causes vomiting and watery diarrhea for three to eight days, along with fever and abdominal pain, according to the U.S. Centers for Disease Control and Prevention.

Hamburg said that PCV1 may have been present in Rotarix since the vaccine was developed. The contamination was found by independent researchers using new virus-spotting technology, she said.

Follow-up FDA analysis has confirmed the presence of PCV1 in Rotarix, Hamburg added. "FDA is investigating how the PCV1 DNA came to be present in the vaccine," she said.

The other vaccine available to protect against rotavirus is RotaTeq, also delivered by mouth and made by Merck. RotaTeq was licensed by the FDA in 2006 so most children vaccinated in the United States received RotaTeq, Hamburg said.

RotaTeq is made using a different method, she noted. "Preliminary tests on the RotaTeq vaccine by an academic research team and FDA have not shown the presence of PCV1 DNA," Hamburg said.

RotaTeq requires three doses while Rotarix requires two. That means that children who have already gotten one shot of Rotarix should now get two shots of RotaTeq to be fully vaccinated, Hamburg said.

She stressed that the the FDA recommendation applies only to the United States. Other countries where rotavirus is more common and severe may choose to continue recommending Rotarix. "Such a decision would be very understandable," she said.

In several weeks, the FDA is having an expert advisory committee meeting to make additional recommendations on the use of rotavirus vaccines, Hamburg said.

Thomas Breuer, head of global clinical R&D and chief medical officer of biologicals at GlaxoSmithKline, said in a statement that, "no safety issue has been identified by external agencies or GSK. GSK is committed to patient safety and to the highest manufacturing standards for all our vaccines and medicines. We are already working closely and discussing this finding with regulatory agencies around the world."

"GSK is now reviewing how best to replace, in a timely way, the cell bank and virus seeds used as base production material. In the meantime, and in accordance with the regulators, the company will continue to manufacture Rotarix to the existing approved production and quality standards to meet public health needs worldwide," the company added.

More information

For more on rotavirus, head to the U.S. Center for Disease Control and Prevention.



SOURCES: March 22, 2010, press conference with: Margaret Hamburg, M.D., Commissioner, U.S. Food and Drug Administration; March 22, 2010, news release, GlaxoSmithKline


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Anthem Blue Crosss Announcement That It Will Temporarily Suspend a 39% Health Insurance Rate Increase Should Not Deter Immediate Legislative Action
2. Unaware of Laws, Many Parents Not Using Booster Seats for Older Children
3. Tampa Bay Vein Treatment and Cosmetic Dermatology Practice Using New Laser Technology Some Say is the Latest Breakthrough
4. Best Selling, Non Toxic Skin Brightener Does the Job Using Safe, Healthy Ingredients and Introduces New Anti Aging Ingredients
5. Using new approach, Mayo Clinic researchers find level of gene alters risk of Alzheimers disease
6. Family history is strong predictor of obstructive coronary artery disease using CCTA
7. Parrish Medical Center Sees 30 Percent Improvement in Mortality Using Real-Time Clinical Surveillance Solution from Thomson Reuters
8. SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone
9. Groundbreaking Study Using Ultrasound for the Treatment of Intracerebral and Intraventricular Hemorrhage Stroke Shows Promise
10. Rockland County Landlord Agrees to Settlement With United States to Protect Fair Housing Rights of Tenants With Mental Disabilities
11. Register Online for this Year's Horst Senior Living Conference on April 8 Featuring Keynote Speaker and Senior Housing Expert Jim Moore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and Center for Autism and ... at Chuck E. Cheese’s locations throughout New England, New York and New Jersey to ... experience the fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. , ...
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be participating as ... the event will take place February 23-25, 2017 at the Calvin L. Rampton Salt ... #909 with three new ambulances on display. , “JEMS is a ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 — ... looking to reduce their regulatory burden? Pay dividends in enhanced and predictable ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter ... Show on the Pet Life Radio network. The episode, which was posted this ... topics including: what factors led to Park Cities Pet Sitter’s being awarded the 2017 ...
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data has ... introduced an innovative workstation designed to reduce nursing fatigue while enhancing productivity. Based ... Workstation offers a lightweight, highly mobile, multi-functional alternative to the limitations of handheld ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017 According to a new market ... Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of Liquids), and End ... by MarketsandMarkets, the market is expected to reach USD 330.6 Million ... of 3.7% from 2016 to 2021. ... ...
(Date:2/17/2017)... -- Research and Markets has announced the addition of the ... offering. ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
(Date:2/17/2017)... 17, 2017  BioDigital, Inc., creators of the ... their 3D body mapping technology with eClinicalWorks, a ... integration will be used to capture and present ... the human body. BioDigital pilots show using a ... also increasing the precision of clinical annotations compared ...
Breaking Medicine Technology: